NCT05397665 - Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

October 12, 2024

Study Completion Date

October 31, 2026

Conditions

Hereditary Neuropathy Caused by SORD Deficiency

Interventions

DRUG

AT-007

AT-007, aldose reductase inhibitor

DRUG

Placebo

Liquid oral suspension

Trial Locations (10)

University of Rochester, Rochester

University of Pennsylvania, Philadelphia

"Fondazione IRCCS Istituto Neurologico Carlo Besta", Milan

University of Miami, Coral Gables

University of Iowa, Iowa City

University of Colorado, Aurora

Massachusetts General Hospital, Boston

Hassman Research Institute, Berlin

Axon Clinical, s.r.o., Prague

University College of London, London